Institute of Social and Preventive Medicine (IUMSP), CHUV and Faculty of Biology and Medicine, Biopôle 1-Route de la Corniche 2, CH-1066 Epalinges, Switzerland.
Atherosclerosis. 2011 Nov;219(1):253-8. doi: 10.1016/j.atherosclerosis.2011.07.117. Epub 2011 Aug 4.
A pleiotropic effect of statins has been reported in numerous studies. However, the association between statin use and inflammatory cytokines is controversial. We examined the associations between statin use and C-reactive protein (CRP), tumour necrosis factor α (TNF-α), interleukin-1β (IL-1β) and interleukin-6 (IL-6) in a healthy Caucasian population.
Cross-sectional study of 6184 participants aged 35-75 years from Lausanne, Switzerland. Cytokines were assessed by multiplexed particle-based flow cytometric assay. Self-reported history of medication was collected for statins and other medication. 99 participants without cytokine data were excluded.
Among the 6085 participants, 2289 (37.6%), 451 (7.4%) and 43 (0.7%) had IL-1β, IL-6 and TNF-α levels below detection limits, respectively. On multivariate analysis adjusting for age, gender, smoking status, body mass index, hypertension, diabetes, baseline cardiovascular disease, total cholesterol, anti-inflammatory use, other cytokine modifying drugs and other drugs, participants on statins had significantly lower CRP levels (adjusted mean±standard error: 1.22±1.05 vs. 1.38±1.04 mg/L for use and non-use, respectively, p<0.01 on log-transformed data). Conversely, no association was found between statin use and IL-1β (p=0.91), IL-6 (p=0.25) or TNF-α (p=0.28) levels. On multivariate analysis, individuals in the statin group (β coefficient=-0.12; 95% CI=-0.21, -0.03) had lower levels of CRP as compared to those in the reference group (i.e. those not using statin). However, no significant associations were observed between IL-1β, IL-6 and TNF-α and statins.
Individuals on statins have lower CRP levels; conversely, no effect was found for IL-1β, IL-6 and TNF-α levels.
许多研究报告了他汀类药物的多效性。然而，他汀类药物使用与炎性细胞因子之间的关联仍存在争议。我们在一个健康的白种人群体中研究了他汀类药物使用与 C 反应蛋白（CRP）、肿瘤坏死因子-α（TNF-α）、白细胞介素-1β（IL-1β）和白细胞介素-6（IL-6）之间的关联。
这项来自瑞士洛桑的横断面研究纳入了 6184 名年龄在 35-75 岁的参与者。通过基于颗粒的多重流式细胞术检测细胞因子。他汀类药物和其他药物的用药史由参与者自报告。排除了 99 名没有细胞因子数据的参与者。
在 6085 名参与者中，分别有 2289 名（37.6%）、451 名（7.4%）和 43 名（0.7%）的 IL-1β、IL-6 和 TNF-α水平低于检测下限。在校正年龄、性别、吸烟状况、体重指数、高血压、糖尿病、基线心血管疾病、总胆固醇、抗炎药物使用、其他细胞因子调节药物和其他药物后，接受他汀类药物治疗的参与者 CRP 水平显著降低（调整后平均±标准误差：使用他汀类药物组为 1.22±1.05mg/L，未使用他汀类药物组为 1.38±1.04mg/L，对数转换数据的 p<0.01）。相反，他汀类药物使用与 IL-1β（p=0.91）、IL-6（p=0.25）或 TNF-α（p=0.28）水平之间未见关联。在多变量分析中，与参照组（即未使用他汀类药物的组）相比，他汀类药物组的个体（β系数=-0.12；95%CI=-0.21，-0.03）的 CRP 水平更低。然而，IL-1β、IL-6 和 TNF-α与他汀类药物之间未观察到显著关联。
使用他汀类药物的个体 CRP 水平较低；相反，IL-1β、IL-6 和 TNF-α 水平没有变化。
